|
|
March 14, 2013
March/April 2013 AAPM Newsletter - is now available in ‘PDF format’ on the
AAPM website along with iPad and Android tablet versions. Some of you may have
experienced difficulty reading with the FLIPBOOK version and hence the switch.
Apply Now for Grants & Fellowships
Applications are being accepted for the Research Seed Funding Grant and the AAPM/RSNA Fellowship for the Training of a Doctoral Candidate in the Field of Medical Physics. Learn more online.
This Issue
HEALTH AND HUMAN SERVICES UPDATES
MEDICARE
. CMS Announces Coverage Decision for PET
JOINT COMMISION
. March 6, 2013
. February 27, 2013
. February 20, 2013
. February 13, 2013
. February 6, 2013
MEETINGS
. Radiation Oncology Program Accreditation Meeting: Online Evaluation System Available
. Hub and Spoke Residency Models Workshop: Online Evaluation System Available
. 3rd CT Dose Summit: Strategies for CT Scan Parameter Optimization: March 15 - 16, 2013; Phoenix, Arizona
. AAPM Spring Clinical Meeting: March 16 - 19, 2013; Phoenix, Arizona
. 2013 AAPM Summer School: June 16 - 20 , 2013; Colorado Springs, Colorado
. AAPM Annual Meeting & Exhibition: August 4 - 8, 2013; Indianapolis, Indiana
. Chapter Meetings
WEBSITE UPDATES
. NEW! Many older interviews with prominent medical physicists available in
flash video for immediate viewing
. Call for Applications for AAPM Website Editor
. 2013 NIH Regional Seminar on Program Funding & Grants Administration in
Baltimore, June 26-28
. Call for applications: Editors for Therapy and Imaging Physics for the journal
Medical Physics
. Just released - Volume 2 of Controversies in Medical Physics
. News for ABR candidates
|
| |
MEDICARE
CMS Announces Coverage Decision for PET
The Centers for Medicare & Medicaid Services (CMS) has determined that, unless
there is a specific national coverage determination, local Medicare Administrative
Contractors (MACs) may determine coverage within their respective jurisdictions
for positron emission tomography (PET) using radiopharmaceuticals for their Food
and Drug Administration (FDA) approved labeled indications for oncologic imaging.
The effect of this decision is to remove the national non-coverage for FDA approved
labeled oncologic uses of radiopharmaceuticals that are not more specifically
determined nationally. Thus this decision does not change coverage for any use
of PET using radiopharmaceuticals FDG (2-deoxy-2-[F-18] fluoro-D-Glucose
(fluorodeoxyglucose)), NaF-18 (fluorine-18 labeled sodium fluoride), ammonia N-
13, or rubidium-82 (Rb-82). This decision does not prevent CMS from determining
national coverage for any uses of any radiopharmaceuticals in the future, and if such
determinations are made, a future determination would supersede local contractor
determination.
 See Full Article | Back to Top
|
